Eagle Health Investments LP: ULTRAGENYX PHARMACEUTICAL IN (RARE): Quarterly 13F Position History
As of Q2 2026, Eagle Health Investments LP reported 884,121 shares of ULTRAGENYX PHARMACEUTICAL IN (RARE), worth $29.5M and representing 4.9% of its 13F equity book. The position first appeared in Q1 2024 and has been disclosed across 10 13F-HR filings in Pactolio's tracked window.
- 884,121Shares Held (Latest Filing)
- $29.5MReported Market Value (Latest Filing)
- 4.9%Portfolio Weight (% of 13F Equity Book)
- 0Quarter-over-Quarter Share Change
- +$11.0MQuarter-over-Quarter Value Change
- 884,121Peak Reported Shares (Historical)
Quarterly 13F-HR Disclosure History Source: SEC 13F-HR filings, 10 quarter s
| Quarter | Shares | QoQ Share Change | Share Change (%) | Market Value | Weight | Implied Price |
|---|---|---|---|---|---|---|
| Q2 2026 | 884,121 | 0 | – | $29.5M | 4.9% | $33.4 |
| Q1 2026 | 884,121 | +884,121 | – | $18.5M | 3.9% | $20.9 |
| Q4 2025 | 0 | 697,000 | -100.0% | $0 | 0.0% | – |
| Q3 2025 | 697,000 | +69,400 | +11.1% | $21.0M | 5.5% | $30.1 |
| Q2 2025 | 627,600 | 0 | – | $22.8M | 5.6% | $36.4 |
| Q1 2025 | 627,600 | 0 | – | $22.7M | 5.9% | $36.2 |
| Q4 2024 | 627,600 | +65,900 | +11.7% | $26.4M | 6.5% | $42.1 |
| Q3 2024 | 561,700 | +37,200 | +7.1% | $31.2M | 6.0% | $55.5 |
| Q2 2024 | 524,500 | +224,800 | +75.0% | $21.6M | 3.9% | $41.1 |
| Q1 2024 | 299,700 | – | – | $14.0M | 2.7% | $46.7 |
Methodology & FAQ
How This Position History Is Sourced
Each row is one SEC Form 13F-HR filing disclosing this position. Share count, market value, and reported quarter are taken verbatim from the filing; portfolio weight is recomputed against the same filing's total reported equity book. Implied price-per-share is market value divided by shares, a quarter-end mark rather than the manager's cost basis. See the full methodology document for the normalization rules.
When did Eagle Health Investments LP first disclose a RARE position in 13F-HR filings?
Eagle Health Investments LP first reported ULTRAGENYX PHARMACEUTICAL IN (RARE) on its 13F-HR filing for the period ending 2024-03-31 (Q1 2024). The position has appeared on 10 reported quarters within Pactolio's tracked window.
What was Eagle Health Investments LP's most recent quarter-over-quarter share-count change in RARE?
Eagle Health Investments LP held the same 884,121 shares of RARE between Q1 2026 and Q2 2026, so the reported share count was unchanged quarter-over-quarter.
Does the implied price-per-share represent Eagle Health Investments LP's cost basis in RARE?
No. The implied price-per-share column is the 13F-HR reported market value divided by reported share count on the filing date (end of quarter). It is a quarter-end mark, not a cost basis or transaction price. Use it as a sanity check on the value column, not as an indicator of the manager's entry or exit price.